Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:23:53.095Z.
Calculation as of: 2026-10-06T16:23:53.095Z.
Quote observation: 2026-10-06T16:11:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7269c43ec051f04bc9b25698fa87f96476c1bd81d443a59abbb4ab2a9593cf8e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
NeuroSense Therapeutics Ltd.
Market Cap
$7.08M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.31M
Price/FCF Ratio
N/A
TTM Avg
41006.18
3Y Avg
41006.18
5Y Avg
41006.18
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.08M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.07M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.16M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.29M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | 41006.18 | 41006.18 | 41006.18 |
| Longeveron Inc. (LGVN)vs › | $7.36M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.80M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.66M | N/A | 6.05 | 13.36 | 13.36 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
